https://prabadinews.com/

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938
endo-expands-voluntary-recall-of-clonazepam-orally-disintegrating-tablets,-usp-(c-iv)-due-to-potential-product-carton-strength-mislabeling Drug Test
  • October 27, 2025

Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling

Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously…
Drug Test
  • October 25, 2025

A Meta‐Analysis of International Flunixin Pharmacokinetics in Horses: Toward Regulatory Harmonization and Individualized Detection Times Using Bayesian Paradigm

A meta-analysis of flunixin concentrations in 65 horses from four countries estimated pharmacokinetic parameters. Considering the estimated plasma-to-urine ratio, raising…
fda-approves-revumenib-for-relapsed-or-refractory-acute-myeloid-leukemia-with-a-susceptible-npm1-mutation Drug Test
  • October 24, 2025

FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation

On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed…
expanded-access-|-information-for-institutional-review-boards-(irbs) Drug Test
  • October 24, 2025

Expanded Access | Information for Institutional Review Boards (IRBs)

Learn more about what IRBs should consider when reviewing Individual Patient Expanded Access Requests.
expanded-access-|-information-for-industry Drug Test
  • October 24, 2025

Expanded Access | Information for Industry

Expanded Access information for medical product companies and other industry stakeholders
expanded-access-|-information-for-physicians Drug Test
  • October 24, 2025

Expanded Access | Information for Physicians

Expanded Access: Physicians’ Page
expanded-access-(compassionate-use)-submission-data Drug Test
  • October 24, 2025

Expanded Access (Compassionate Use) Submission Data

Expanded Access (Compassionate Use) Submission Data
spartan-may-be-harmful-due-to-hidden-drug-ingredient Drug Test
  • October 23, 2025

SPARTAN may be harmful due to hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use SPARTAN, a product promoted and sold for…
fda-approves-belantamab-mafodotin-blmf-for-relapsed-or-refractory-multiple-myeloma Drug Test
  • October 23, 2025

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma

On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody…
2024-first-generic-drug-approvals Drug Test
  • October 23, 2025

2024 First Generic Drug Approvals

2024 First Generic Drug Approvals